Liver fibrosis may be diagnosed and staged — no fibrosis (stage F0), mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) — with the use of clinical parameters and ...
New European and Latin American guidelines on the use of noninvasive tests for liver evaluation are the first to specifically address an approach that has become the standard in much of the developed ...
As the management landscape of primary biliary cholangitis (PBC) changes, new second-line options offer effective ...
Steatotic liver disease (commonly called fatty liver disease) progresses silently. Even in the absence of noticeable symptoms, changes begin to unfold inside the liver. While hepatic fat accumulation ...
Research finds that TyGWHtR, a simple metabolic index, predicts non-alcoholic fatty liver disease in older adults, ...
On Thursday, the Food and Drug Administration announced its approval of the first ever therapeutic treatment targeting metabolic dysfunction-associated steatohepatitis (MASH). This represents a ...
On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight ...
WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- More than 100 million people in the U.S. are affected by some form of liver disease, but only 4.5 million adults have been diagnosed with the condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results